Why Supplements Pass Release Testing but Fail UAE Label Claims: Overage, Hot-Climate Stability and the 80–120% Window

In Spec at Release, Out of Spec in a Dubai Warehouse

A supplement can meet every release specification and still fail its label claim months later. Potency is measured on the day a batch is made, but the consumer reads the label on the shelf, often after storage in heat and humidity. In the UAE, that gap matters twice: the claim must hold in hot-climate conditions, and the evidence must satisfy the authority that reviews the product. For teams in nutraceutical product development, this article explains how to design overage, shelf-life stability testing for supplements and claim evidence so that potency stays inside the 80–120% label-claim window through shelf life.

Take a hypothetical vitamin D3 tablet that assays 88% of label claim at release, inside the 80–120% window. After 18 months in a hot warehouse and delivery vans, the same product assays 77%, below the 80% floor (Figure 1). Nothing failed at release. The batch met its specification, but the formula carried no supplement label claim overage, so the potency lost in storage took it under the floor.

The loss is 11 percentage points, or 12.5% of the starting potency (88% × 0.875 = 77%). Had the batch been released near 97%, the target given by the Figure 2 formula with a 5-point margin, the same loss would have left it at about 85% at month 18. The product, the storage and the loss are identical; only the release target differs. The rest of this article shows how to set that target and how to prove it.

Release vs Shelf-Life: The 80–120% Label Claim Window

Release Testing vs Shelf-Life Specification: Why Passing at Release Is Not Enough

A release assay shows potency at batch release. A shelf-life specification sets what the product must meet at expiry, and the two can differ ^[9]. A batch that passes the first has not yet shown it will pass the second. Throughout this article, Requirement means a rule stated by the authority; FRL design target means a stricter control we recommend.

The 80–120% Label Claim Window Explained

Requirement: Annex 2 of Dubai Municipality’s Technical Guidelines for Health Supplements, Version 2, specifies 80–120% of label claim for quantitative vitamin and mineral assays ^[2]. Section 6 also requires acceptable product stability and an adequate shelf life. The cited provisions do not state the time point at which the 80–120% range applies. For botanicals and probiotics, this article treats the same window as an FRL design practice, not a confirmed regulatory requirement.

FRL design target: show that the product meets its justified potency specification through the whole proposed shelf life, not only at release.

Who Regulates Your Supplement: Montaji, EDE and Abu Dhabi

More than one authority publishes a supplement pathway, so confirm the route first. The Dubai Municipality guideline covers supplements that make no disease claim and are registered through Montaji. Section 8.5 makes registration valid for five years, with renewal subject to review ^[2]. The Emirates Drug Establishment (EDE) separately lists dietary supplements in its healthcare-product marketing authorisation, valid five years from committee approval ^[4]. Which route applies depends on the product and the emirate, so confirm the pathway with the authority before you build the dossier. In Abu Dhabi, the Department of Health publishes a list of adulterated products ^[1]. For how UAE authorities classify borderline products, see our cosmeceuticals guide.

Formulator’s note: what this means for your development plan

Do not set the release target until you have loss data from the final pack. Overage that is guessed early tends to break one of the two ceilings later: 120% of label claim or the ingredient’s upper limit. Build the order into the plan: fix the claim, test the final pack at 30°C and at 40°C/75% RH, estimate the loss (L), then set the release target. If the result exceeds either ceiling, change the pack, shelf life or formulation rather than adding more ingredient. This article is based on Dubai Municipality’s guideline Version 2 (4 May 2024); confirm it is still the current version before you finalise the dossier.

What You Can Claim, and the Evidence Each Claim Needs

Health Claims and the >30% RDA Threshold

Requirement: a vitamin or mineral supplementation claim is permitted only when the product provides more than 30% of the recommended daily allowance (RDA). The rule covers that claim type only ^[2].

Structure/Function Claims vs Prohibited Claim Categories

A structure/function claim describes an ingredient’s role in normal body function. It needs ingredient-based evidence and, when necessary, product-based evidence (finished-formula data) ^[2]. Annex 4 prohibits claims across 20 disease groups, as well as absolute-safety or guaranteed-result assurances and claims of longevity or memory enhancement ^[2].

The FRL Claim-to-Evidence Matrix

Table 1 maps each claim type to the evidence, test and acceptance basis needed for label claim potency compliance.

Table 1. Claim-to-evidence matrix: claim, evidence, test, and acceptance basis

Build the claim into a test plan before the dossier. Table 1 shows what each claim must prove in the lab. Our team can turn it into a test plan for your product. Request a claim-to-evidence test plan

Why 25°C Stability Data Is Not Enough for the Gulf

How Active Ingredients Degrade Under Hot-Climate Storage

Heat and moisture speed up potency loss, and the pack controls how much moisture reaches the product. WHO requires stability testing in the container-closure system proposed for marketing ^[9]. Your active ingredient degradation rate must therefore come from the finished product’s own data, not from literature values for the raw ingredient.

Climatic Zones IVa and IVb: Choosing a Long-Term Condition for the UAE

Requirement: Dubai Municipality sets no numeric stability protocol ^[2]. Table 2 is an FRL design framework, not a regulatory condition. WHO Annex 10 lists 30°C/65% RH (zone IVa) or 30°C/75% RH (zone IVb) as long-term conditions, chosen by the climatic zone where the product will be marketed ^[9]. Dubai Municipality does not assign a zone, so the choice is a design decision.

Table 2. FRL stability-design framework using WHO Annex 10 conditions ^[9]

In shelf-life stability testing for supplements, file real-time and accelerated stability data from the final pack. For an accelerated stability study under ICH Q1A(R2) (Step 4, 6 February 2003), follow its design rules ^[5]. Q1A(R2) covers new drug products, so it guides supplement studies without binding them. ICH is revising Q1, with Step 4 adoption targeted for November 2026 in the expert working group’s work plan ^[7][8].

Overage Logic: Inside 80–120% and Under the Upper Limit

Release potency above 100% of label claim is the supplement label claim overage. It has to be large enough to absorb the loss expected by expiry, and small enough to stay under two ceilings. Figure 2 sets out the two release targets:

• Minimum release target = (80% + method margin + process margin) ÷ (1 − L). This keeps the product at or above the 80% floor at expiry.
• Full-label release target = 100% ÷ (1 − L). This holds the full 100% of label claim at expiry.

Here, L is the fraction of release potency lost by expiry, and the margins are percentage points of label claim at expiry. Both results must stay at or below 120% of label claim and below the ingredient’s upper limit.

Sizing the Buffer: Release Targets and Their Limits

Designing Overage: Calculating the Right Potency Buffer

This overage calculation for dietary supplements divides rather than adds: a 10% loss of release potency is not the same as 10 percentage points of label claim. A USP stakeholder presentation builds overage from stability loss, processing variability and testing variability, while keeping the result below the upper limit ^[10]. Estimate L by regression of real-time data, using the conservative 95% confidence limit, as ICH Q1E does for shelf life ^[6]. The method margin comes from assay measurement uncertainty ^[3]; the process margin comes from batch-to-batch variation.

Table 3. Release targets by potency loss: 25 µg vitamin D3 tablet, 5-point margin (hypothetical)

One tablet daily; 120% of label claim is 30 µg, well below the 100 µg/day limit.

When Overage Is the Wrong Fix

Requirement: both the 120% ceiling and the ingredient’s upper limit apply ^[2]. If the target exceeds either, change the form, pack, shelf life or claim instead; reformulation can shorten shelf life, so re-test after any change. A mean near 100% can also hide individual units below 80%, so test content uniformity as well as the batch average.

Evidence Snapshot: What 13 Vitamin C Supplements Show About Label Claims and Storage

The question: a manufacturer must show that vitamin C potency matches the label and keeps matching it through shelf life. A 2024 study of 13 commercial ascorbic acid supplements sold in Estonia looked at both points ^[11].

What the authors did: they measured ascorbic acid by HPLC, then re-tested the opened packages after 16 months of storage.

• 11 of 13 products measured 78.5–115.2% of the nominal amount; two measured only 54.6–56.3%.
• Three products fell outside the European Commission tolerance range reported in the study (−20% to +50%).
• Four products showed a statistically significant decrease (about 7–21 mg) after 16 months; the other samples did not change.
• Loss was product-specific, which is why stability data must come from your own formulation and pack.

The study was not run under hot-climate conditions, so it shows how label accuracy and in-use stability vary between products, not Gulf degradation rates. The lesson for product development is to verify the label claim by assay and to keep product-specific stability data.

Release passed. What does month 18 say? Our nutraceutical formulation team can review your 30°C real-time stability plan. Review my 30°C stability plan

Contaminants: Turning ppm into Per-Day Limits

Requirement: Dubai Municipality sets adult heavy-metal limits per day of product intake, not per gram of product ^[2]. A laboratory reports results in ppm (mg/kg), so the result must be converted before it can be compared with the limit:

ppm (mg/kg) × daily intake (g/day) = µg/day

Table 4. Adult heavy-metal limits per day: arsenic, mercury, lead and cadmium ^[2]

Worked example, assuming a daily intake of 3 g: a lead result of 5 ppm gives 15 µg/day, which passes against the 20 µg/day limit. A result of 8 ppm gives 24 µg/day, which fails.

The same limits can be turned around into a maximum ppm for a given daily intake: limit ÷ g/day. At 3 g/day, the maximum results are 3.3 ppm for arsenic, 6.7 ppm for mercury, 6.7 ppm for lead and 2.0 ppm for cadmium. A larger daily intake lowers the allowable ppm, so a batch that passes at 3 g/day can fail if the label directs 5 g/day.

Set your ppm specification from the highest daily dose on the label, then test the finished product, not only the raw materials.

Conclusion

Passing release proves a batch was right on day one; the label claim has to hold on the shelf. Test the final pack at hot-climate conditions, size supplement label claim overage from your own loss data inside both ceilings, and confirm the regulator and guideline version before filing.

For Brands & Formulators: What the Lab Adds to the Montaji Dossier

Building Claim Evidence: Stability Data That Holds Up at Registration

The Dubai guideline asks for a manufacturer’s analysis report (Section 9.3) and a certified-laboratory report using accredited methods (Section 9.5) ^[2]. FRL’s nutraceutical formulation services add four deliverables: a final-pack stability protocol, a loss estimate, a method-uncertainty statement, and a certificate of analysis (CoA) read against shelf-life specifications. They support, but do not replace, the UAE supplement registration requirements. For the wider submission, see our overview of nutraceutical dossier preparation.

Common Failure Modes and How to Prevent Them

Three study-design gaps weaken stability evidence ^[9]:

• Pulls stop short of shelf life. A study that ends at month 12 cannot support a 24-month expiry. Prevention: pull samples to the full claimed period.
• Non-final pack. The closure and liner change how much moisture gets in. Prevention: test the marketed pack.
• Unrepresentative batch. A pilot lot may not match commercial blending. Prevention: use batches made by the commercial process.

A Practical Framework for Nutraceutical Product Development

Use these five steps when developing a nutraceutical formulation for a dietary supplement:

1. Claim: fix the claim category and wording first, because they set the evidence required.
2. Evidence: list the test, acceptance range and upper limit for each claim (Tables 1 and 4).
3. Stability design: run the final pack at 30°C and at 40°C/75% RH (Table 2).
4. Overage: set the release target within 120% of label claim and the ingredient’s upper limit (Figure 2 and Table 3).
5. Dossier: confirm the route and guideline version, then attach the stability and certified-laboratory reports.

Develop Your Supplement with the Label Claim Built In

Food Research Lab’s nutraceutical product development services cover formulation, shelf-life testing and claim evidence, so your product is designed to hold its label claim at the end of shelf life. Share your product, target market and claim through our contact page, and our team will outline the tests and overage design it needs.

1. Department of Health – Abu Dhabi. (n.d.). Adulterated products. https://www.doh.gov.ae/en/resources/Adulterated-Products
2. Dubai Municipality. (2024, May 4). Technical guidelines for health supplements (DM-HSD-GU29-TGHS2, Version 2). https://dmpmedia.dm.gov.ae/uploads/2024/07/DM-HSD-GU29-TGHS2_Technical-Guidelines-for-Health-Supplements_V2.pdf
3. Ellison, S. L. R., & Williams, A. (Eds.). (2012). Quantifying uncertainty in analytical measurement (3rd ed.; EURACHEM/CITAC Guide CG 4). Eurachem. https://www.eurachem.org/images/stories/Guides/pdf/QUAM2012_P1.pdf
4. Emirates Drug Establishment. (n.d.). Issuance of marketing authorization for a healthcare product. https://www.ede.gov.ae/en/w/issuance-of-marketing-authorization-for-a-healthcare-product
5. International Council for Harmonisation. (2003, February 6). Stability testing of new drug substances and products Q1A(R2) (Step 4 version). https://database.ich.org/sites/default/files/Q1A(R2) Guideline.pdf
6. International Council for Harmonisation. (2003, February 6). Evaluation for stability data Q1E (Step 4 version). https://database.ich.org/sites/default/files/Q1E Guideline.pdf
7. International Council for Harmonisation. (2025, April 11). Q1 Stability testing of drug substances and drug products (Draft guideline, Step 2). U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1-stability-testing-drug-substances-and-drug-products
8. International Council for Harmonisation. (2026). ICH Q1 Expert Working Group work plan. https://database.ich.org/sites/default/files/ICH52_Q1_EWG_WorkPlan_2026_0318.pdf
9. World Health Organization. (2018). WHO guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-second report (WHO Technical Report Series, No. 1010, Annex 10). https://www.who.int/publications/m/item/trs1010-annex10
10. Yoo, S. J., Walfish, S. L., Atwater, J. B., Giancaspro, G. I., & Sarma, N. (2016, June 1). Factors to consider in setting adequate overages of vitamins and minerals in dietary supplements [Conference presentation]. USP Dietary Supplements Stakeholder Forum. https://usp.org/sites/default/files/usp/document/get-involved/stakeholder-forums/04a-stimuli-articles-overages-2016-06-01.pdf
11. Ain, R., Meos, A., Vutt, A., Kirsimäe, H., Ilina, T., Kovaleva, A., & Koshovyi, O. (2024). The content and stability of ascorbic acid in commercial food supplements. ScienceRise: Pharmaceutical Science, 5(51), 28–37. https://doi.org/10.15587/2519-4852.2024.313637